Gottfried Konecny, MD
Enriched profileProfessor of Medicine, Division of Hematology/Oncology; Lead Clinician for Gynecologic Oncology · David Geffen School of Medicine at UCLA
Gottfried Konecny is Professor of Medicine, Division of Hematology/Oncology; Lead Clinician for Gynecologic Oncology at David Geffen School of Medicine at UCLA. OpenAlex indexes 415 publications with 21,205 citations (h-index 59); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Gottfried E. Konecny, MD, is Professor of Medicine, Division of Hematology/Oncology at David Geffen School of Medicine at UCLA / UCLA Health (Westwood Cancer Care). The public record shows 415 publications with 21,205 citations (h-index 59), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Cancer Genomics and Diagnostics. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 12 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Ovarian cancer diagnosis and treatment
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 124.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Sponsor: NiKang Therapeutics, Inc.
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Sponsor: Jonsson Comprehensive Cancer Center
- Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Industry payments
Updated 15 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202543 payments$55,129openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20257 payments$12,130openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.8%PD-1 inhibitor50%Pembrolizumab100%Part B, office-administered≥25 patientsMicrotubule Inhibitor19.9%Paclitaxel100%Part B, office-administered≥17 patients+ 2 more classes in this area
Metabolism & gastrointestinal
27%Other antiemetics23.9%Fosaprepitant100%Part B, office-administered≥28 patientsSerotonin-3 Receptor Antagonist3.1%Palonosetron hcl71%Ondansetron hydrochloride27%Ondansetron Hcl2%Part D + Part B≥37 patients+ 2 more classes in this area
Sensory organs
2%Corticosteroid2%Dexamethasone sodium phosphate100%Part B, office-administered≥36 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 15 Oct 2026
36 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1402: Real world clinical outcomes with trastuzumab deruxtecan in HER2 expressing ovarian and endometrial cancer.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer.
JCO precision oncology
Article2026 - Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.
Nature communications
Article2026 - Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers.
Cancer discovery
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/gottfried-konecny-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Gottfried-Konecny-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- X / Twitter
twitter.com/OncLive/status/1772790695348060590
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Professor-in-Residence
Obstetrics and Gynecology, UCLA David Geffen School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗ - Member
Signal Transduction and Therapeutics Research Program, UCLA Jonsson Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviews
press, podcasts and appearances- Recurring video expert commentator on ovarian cancer therapeutics (PARP inhibitors, mirvetuximab soravtansine) for OncLive
including coverage tied to SGO Annual Meeting on Women's Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Finn, MD
David Geffen School of Medicine at UCLA
Edward Garon, MD
David Geffen School of Medicine at UCLA
Donald Tashkin, MD
David Geffen School of Medicine at UCLA
Aditya Bardia, MD
David Geffen School of Medicine at UCLA
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute